Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.41 is 88% above its 5-year average of -19.82, near the high end of its 5-year range (-46.29–0.64).
73.55% above its 12-month average of -9.11.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 0.49.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 23 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T17:22:36.662Z. Historical observations retain their original dates. Historical series through 2026-05-05.
EARNINGS PER SHARE (EPS)
-2.41
EARNINGS PER SHARE (EPS) AVG TTM
-9.11
EARNINGS PER SHARE (EPS) AVG 3Y
-20.57
EARNINGS PER SHARE (EPS) AVG 5Y
-19.82
EARNINGS PER SHARE (EPS) AVG 10Y
-29.92
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+73.55%
CURRENT VS 3Y AVG
+88.28%
CURRENT VS 5Y AVG
+87.84%
CURRENT VS 10Y AVG
+91.94%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Seres Therapeutics, Inc.
Market Cap
$27.45M
Earnings Per Share (EPS)
-2.41
TTM Avg
-9.11
3Y Avg
-20.57
5Y Avg
-19.82
Market Cap
$28.22M
Earnings Per Share (EPS)
-0.62
TTM Avg
-0.83
3Y Avg
-1.05
5Y Avg
-1.29
Market Cap
$26.23M
Earnings Per Share (EPS)
-0.50
TTM Avg
-0.76
3Y Avg
-1.17
5Y Avg
-2.27
Market Cap
$25.91M
Earnings Per Share (EPS)
N/A
TTM Avg
-0.19
3Y Avg
-0.10
5Y Avg
-0.07
Market Cap
$29.48M
Earnings Per Share (EPS)
-1.87
TTM Avg
-12.30
3Y Avg
-40.98
5Y Avg
-45.74
Market Cap
$29.54M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.42
3Y Avg
-0.82
5Y Avg
-1.14
Market Cap
$29.39M
Earnings Per Share (EPS)
-1.63
TTM Avg
-2.10
3Y Avg
-19.25
5Y Avg
-13.48
Market Cap
$29.81M
Earnings Per Share (EPS)
-4.31
TTM Avg
-4.75
3Y Avg
-350.99
5Y Avg
-43000.60
Market Cap
$30.00M
Earnings Per Share (EPS)
-3.21
TTM Avg
-2.50
3Y Avg
-4.25
5Y Avg
-9.67
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | $27.45M | -2.41 | -9.11 | -20.57 | -19.82 |
| aTyr Pharma, Inc. (ATYR)vs › | $28.22M | -0.62 | -0.83 | -1.05 | -1.29 |
| InspireMD, Inc. (NSPR)vs › | $26.23M | -0.50 | -0.76 | -1.17 | -2.27 |
| iTonic Holdings Ltd. (ITOC)vs › | $25.91M | N/A | -0.19 | -0.10 | -0.07 |
| Quantum Cyber N.V. (QUCY)vs › | $29.48M | -1.87 | -12.30 | -40.98 | -45.74 |
| Context Therapeutics Inc. (CNTX)vs › | $29.54M | -0.48 | -0.42 | -0.82 | -1.14 |
| OneMedNet Corporation (ONMD)vs › | $29.39M | -1.63 | -2.10 | -19.25 | -13.48 |
| GridAI Technologies Corp. (GRDX)vs › | $29.81M | -4.31 | -4.75 | -350.99 | -43000.60 |
| CervoMed Inc. (CRVO)vs › | $30.00M | -3.21 | -2.50 | -4.25 | -9.67 |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.79M | -4.34 | -3.52 | -3.45 | -7.67 |
Trailing EPS (TTM)
$-2.41
Forward EPS (Est.)
$-3.51
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 0.64 |
| 2024-12-31 | -18.86 |
| 2023-12-31 | -17.77 |
| 2022-12-31 | -46.29 |
| 2021-12-31 | -14.30 |
| 2020-12-31 | -22.34 |
| 2019-12-31 | -24.81 |
| 2018-12-31 | -48.57 |
| 2017-12-31 | -44.19 |
| 2016-12-31 | -46.00 |
| 2015-12-31 | -46.60 |
| 2014-12-31 | -9.24 |
| 2013-12-31 | -3.58 |
| 2012-12-31 | -1.75 |
